Ixazomib (Ninlaro), the first oral PI All were approved for use in relapsed/refractory multiple myeloma, although daratumumab was also approved for newly diagnosed disease.

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

CellCentric’s $120 million Series C funding supports late-stage development of inobrodib, a novel oral p300/CBP inhibitor for multiple myeloma. Inobrodib’s mechanism targets MYC and IRF4 expression, ...

While multiple myeloma can be a challenging disease, there is hope for a better future. Continued research, improved treatments and strong support systems offer the potential for patients to live ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients have been told that multiple myeloma is treatable but not curable. Yet data ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Currently, the 3 BsAbs approved, with accelerated approvals, for relapsed/refractory multiple myeloma are teclistamab (Tecvayli; approved in October 2022), elranatamab (Elrexfio; approved in August ...

RAPA-201 is under development for the treatment of relapsed and refractory multiple myeloma, solid tumor, gastric cancer, head and neck cancer, carcinoma of unknown primary, bladder cancer, non-small ...

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy ...

Daratumumab, a human IgGκ monoclonal antibody targeting CD38, has been approved for use as monotherapy or in combination with standard regimens for multiple myeloma. 3,4 The phase 2 CENTAURUS ...

Multiple myeloma is a type of blood cancer that happens in the bone marrow (the soft, spongy tissue inside the bones). Tecvayli attaches to a protein called BCMA that is found on the surface of ...

Potential reasons for delayed treatment initiation of guideline-directed oral medications to treat multiple myeloma (MM), and that demonstrate significant disparities to work at overcoming ...